A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
Study Details
Study Description
Brief Summary
This Window Of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered either by IT injection or by IV route.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Detailed Description
The window of opportunity, Study H-200-002, will examine the effects of study agent (HB-201) on subjects during the "window" between diagnosis of their cancer and their definitive cancer surgery or chemoradiation.
The study will be a 2-arm study design. In Arm 1, the study will enroll subjects with resectable stage I-III human papillomavirus 16 positive (HPV 16+) genotype squamous cell cancer of the oropharynx who are candidates for transoral surgery. Participants will receive a single dose of the study agent HB-201 prior to transoral surgery. Arm 1 will consist of 2 Cohort groups; Cohort 1 will enroll subjects receiving HB-201 as an intratumoral injection and Cohort 2 will enroll patients receiving HB-201 administered intravenously.
In Arm 2, the study will enroll cervical cancer subjects who have locally advanced squamous cell carcinoma, adenocarcinoma, and/ or adenosquamous cell carcinoma with HPV 16+ genotype. Subjects with advanced/metastatic disease that are previously untreated who are planning to undergo upfront chemoradiation for local control are eligible and will receive an intratumoral injection of HB-201 prior to the start of chemoradiation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HB-201 Intratumorally on Day 1 Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx. |
Drug: HB-201 IT
Cohort 1: HB-201 given IT, one (1) time, on day 1.
|
| Experimental: HB-201 Intravenously on Day 1 Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx. |
Drug: HB-201 IV
Cohort 2: HB-201 given IV, one (1) time, on day 1.
|
| Experimental: HB-201 Intratumorally 7 to 14 days before chemoradiation Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype. |
Drug: HB-201 IT
HB-201 will be administered IT, one (1) time, 7 to 14 days prior to definitive chemoradiation.
|
Outcome Measures
Primary Outcome Measures
- Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer. [Approximately 6-8 weeks]
Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay).
- Immunologic response comparing IV and IT administration. [Approximately 6-8 weeks]
Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay).
Secondary Outcome Measures
- Measurement of messenger RNA and expression profiles in tumor specimens using RNA-sequencing (800 genes). [Approximately 6-8 weeks]
Pre and post administration of HB-201
- Assessment of tumor mutational burden (TMB, MSI) in tumor specimens using whole exome sequencing. [Approximately 6-8 weeks]
Pre and post administration of HB-201
- Measure TH1/TH2 proinflammatory cytokines (mesoscale multiplex discovery assay) to characterize metabolic / proteomic changes in serum / plasma [Approximately 6-8 weeks]
Pre and post administration of HB-201
- Measure ctDNA to characterize changes in circulating tumor by NextGen sequencing. [Approximately 6-8 weeks]
Pre and post administration of HB-201
- Characterize t-cell receptor repertoire diversity and clonality, by t-cell receptor sequencing. [Approximately 6-8 weeks]
Pre and post administration of HB-201.
- Clinical evidence of response to HB-201 [Approximately 6-8 weeks]
Change in tumor size per RECIST v1.1
- Toxicity profile of HB-201 [Approximately 30 days post HB-201 administration]
Number and type of adverse events per CTCAE v5.0
Eligibility Criteria
Criteria
Inclusion Criteria:
All subjects:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Confirmed HPV 16+ (human papilloma virus 16 positive) genotype testing of cancer.
-
Disease-free for ≥ 2 years from other curatively treated cancers, with protocol-defined exceptions.
-
Evaluated by cardiologist and/or neurologist if protocol-defined cardiac or neurological event within the last 6 months.
HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2)
-
Newly diagnosed, squamous cell carcinoma or undifferentiated carcinoma of the oropharynx, determined to be resectable.
-
AJCC v8.0 Tumor, Node, Metastasis (TNM) stage I-III, cT1- T3, and cervical nodes N1-N3 based on clinical or radiographic criteria with no evidence of distant metastases.
-
No prior radiation above the clavicles.
-
Must have acceptable renal and hepatic function as defined per protocol.
-
Cohort 2 (intratumoral administration) only: must have a safe and accessible tumor lesion amenable for biopsy and IT administration.
HPV 16+ Cervical Cancer (Arm 2)
-
Newly diagnosed, histologically confirmed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma): International Federation of Gynecology and Obstetrics (FIGO) clinical stages IB to IVB with plan for initial treatment of definitive chemoradiation (platinum agent weekly with radiotherapy) for either curative intent or control of local (pelvic) disease.
-
No prior radiation to the abdomen or pelvis.
-
Must have a safe and accessible tumor lesion amenable for biopsy and IT administration.
-
Must have normal organ and marrow function as defined per protocol.
-
Must not have a known allergy to cisplatin, carboplatin, or compounds of similar biologic composition.
Exclusion Criteria:
All subjects:
-
Treatment with any systemic anticancer therapy within 3 years (unless agreed otherwise between the Sponsor and the Investigator).
-
Treatment with any chronic immunosuppressive medication within 6 months (unless agreed otherwise between the Sponsor and Investigator).
-
Uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension.
-
Live vaccine within 28 days (unless agreed otherwise between Sponsor and Investigator).
-
Known diagnosis of acquired immunodeficiency syndrome (AIDS).
-
Positive Hepatitis B or Hepatitis C tests indicating acute or chronic infection.
-
Intercurrent illness likely to interfere with protocol therapy.
-
Female subjects who are pregnant or breastfeeding.
-
Female subjects of childbearing potential who do not agree to the use of highly effective contraception per protocol.
-
Male subjects with sexual partners of childbearing potential who do not agree to the use of protocol-defined contraception
HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2)
• Primary tumor or nodal metastasis fixed to the carotid artery, skull base, or cervical spine.
HPV 16+ Cervical Cancer (Arm 2)
-
Treatment with chemotherapy for cervical cancer, prior to planned chemoradiation.
-
Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
Sponsors and Collaborators
- Hookipa Biotech GmbH
Investigators
- Study Director: Chief Medical Officer, Hookipa Biotech GmbH
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- H-200-002